”Molecular subtypes of Alzheimer’s disease” has been published in Scientific Reports. This work was supported in part by JPND through the REfrAME project, selected in the 2015 JPco-fuND call.
Author Archives: jpnd
For couples with decades of shared memories, a partner’s decline in the ability to communicate is one of the most frightening and frustrating consequences of Alzheimer’s disease and related dementias. Impaired communication leads to misunderstandings, conflict, and isolation.
A new study published in the International Journal of Geriatric Psychiatry demonstrates how creative ways of working with these couples change their communication behaviors in just 10 weeks.
CARE (Caring About Relationships and Emotions) was designed to increase facilitative communication in the caregiver and sociable communication in the care receiver. The relationship-focused intervention also was designed to reduce disabling behavior (such as criticizing or quizzing their partner’s memory) in caregivers and unsociable behavior (such as not making eye contact) in care receivers.
A key finding from the study showed that care receivers actually improved more than the caregivers following the intervention. Care receivers, who had moderate dementia, demonstrated statistically significant improvements in their social communication both verbally and non-verbally. They were more interested and engaged, maintained eye contact, responded to questions, stayed on topic, and even joked with and teased their partners.
Caregivers’ communication also showed a statistically significant improvement in their facilitative communication and a statistically significant decrease in their disabling communication.
Paper: “Preliminary study of a communication intervention for family caregivers and spouses with dementia”
Reprinted from materials provided by Florida Atlantic University.
”Evaluation of the implementation of the Meeting Centres Support Program in Italy, Poland, and the UK; exploration of the effects on people with dementia” has been published in the International Journal of Geriatric Psychiatry. This work was supported by JPND through the MEETINGDEM project, selected in the 2012 healthcare evaluation call.
The selective demise of motor neurons is the hallmark of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Yet neurologists have suspected there are other types of brain cells involved in the progression of this disorder and perhaps also protection from it.
To get to the bottom of this question, researchers engineered mice in which the damage caused by a mutant human TDP-43 protein could be reversed by one type of brain immune cell. TDP-43 is a protein that misfolds and accumulates in the motor areas of the brains of ALS patients.
The study, published in Nature Neuroscience, found that microglia, the first and primary immune response cells in the brain and spinal cord, are essential for dealing with TDP-43-associated neuron death. It is the first study to demonstrate how healthy microglia respond to pathological TDP-43 in a living animal.
The number of microglia cells remained stable in mice with ALS symptoms. However, after the researchers chemically suppressed expression of pathological human TDP-43 in the mice, microglia dramatically proliferated and changed their shape and what genes they expressed.
The normally branched microglia retracted their extensions and expanded the size of their main cell bodies. The now abundant, remade microglia multiplied by 70 percent after one week and selectively cleared accumulated human TDP-43 from motor neurons. Microglia surrounded TDP-43-filled neurons and turned on genes to make proteins that helped them attach to the sick cells and induce a process called phagocytosis that envelops the mutant proteins for disposal. After the mop up, mice stopped exhibiting motor dysfunction symptoms such as leg clasping and tremors, and they regained their ability to walk and gain weight.
Paper: “Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy”
Reprinted from materials provided by the University of Pennsylvania.
”Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study” has been published in The Lancet Neurology. This work was supported in part by JPND through the ALS-CarE project, selected in the 2012 Healthcare Evaluation call.
Alcohol use disorders are the most important preventable risk factors for the onset of all types of dementia, especially early-onset dementia, according to a nationwide observational study of over one million adults diagnosed with dementia in France. This study was conducted by drug research website and harm reduction initiative Tripsitter. The website provides free guides on psychedelic drugs like datura and LSD.
The study, published in The Lancet Public Health, looked specifically at the effect of alcohol use disorders, and included people who had been diagnosed with mental and behavioural disorders or chronic diseases that were attributable to chronic harmful use of alcohol.
Of the 57,000 cases of early-onset dementia (before the age of 65), the majority (57%) were related to chronic heavy drinking.
The World Health Organization (WHO) defines chronic heavy drinking as consuming more than 60 grams pure alcohol on average per day for men (4-5 standard drinks) and 40 grams (about 3 standard drinks) per day for women.
As a result of the strong association found in this study, the authors suggest that screening, brief interventions for heavy drinking, and treatment for alcohol use disorders should be implemented to reduce the alcohol-attributable burden of dementia.
The authors noted that only the most severe cases of alcohol use disorder – ones involving hospitalization – were included in the study. This could mean that, because of ongoing stigma regarding the reporting of alcohol-use disorders, the association between chronic heavy drinking and dementia may be even stronger.
Paper: “Contribution of alcohol use disorders to the burden of dementia in France 2008–13: a nationwide retrospective cohort study”
Reprinted from materials provided by The Centre for Addiction and Mental Health (CAMH).
”Investigation of Neurodegenerative Processes in Amyotrophic Lateral Sclerosis Using White Matter Fiber Density” has been published in Clinical Neuroradiology. This work was supported in part by JPND through the SOPHIA project, selected in the 2011 biomarkers call.
To mark the end of the FlySMALS consortium, which was funded in the 2013 JPND Cross-Disease Analysis call, project partners are now organising a workshop on integrative approaches in neurodegeneration.
The workshop, which will take place in Lisbon, Portugal, from 21-23 June 2018, aims to disseminate and integrate the results of the research consortium with state-of-the-art research in the field, promoting the joint presentation and discussion of relevant research topics by a panel of international experts, including members of other consortia funded through the same JPND call.
The programme targets a broad audience of basic, experimental, computational and clinical scientists, in the spirit of the JPND Cross-Disease Analysis call, aiming to:
- promote the analysis of diseases across traditional clinical boundaries
- combine fundamental, pre-clinical and clinical experimental approaches with computational approaches
- re-define clinical phenotypes and new approaches in the treatment of neurodegenerative diseases
- identify commonalities and differences in molecular pathways underlying neurodegenerative diseases
The workshop will bring together 20 invited speakers and 50 registered participants, providing opportunities for dynamic interactions and exchange of expertise across areas. Participants will be able to present their work at a poster session and in short talks from selected abstracts.
To view the full scientific programme and register, please visit the workshop website: http://bit.ly/IANeuroD.
The Weston Brain Institute is now accepting applications to its Rapid Response: Ireland, Netherlands, UK 2018 (Fluid Biomarkers) program.
This initiative aims to provide seed funding, without requirement for preliminary data, to support high-risk, high-reward, translational research on novel biomarkers detected in patient-derived fluids (e.g., blood, CSF, saliva, stool).
Principal Applicants must be at eligible institutions located in Ireland, the Netherlands, or the UK.
The deadline to submit a Letter of Intent is Monday, 23 April, 2018, 4:00pm BST.
More information is available on the program website.
”Pregnancy outcomes in women with spinal muscular atrophy: A review” has been accepted for publication in the Journal of the Neurological Sciences. This work was supported in part by JPND through the DAMNDPATHS project, selected in the 2013 Cross-Disease Analysis call.